

## **SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES**

**Ghent, Belgium, 27 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA)** (the "**Company**" or "**Sequana Medical**"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that a total number of 286 Executive Share Options (as defined below) has been exercised.

As a result of this exercise of Executive Share Options, on 27 July 2021 the share capital of the Company has increased from EUR 1,924,846.39 to EUR 1,924,931.96 and the number of issued and outstanding shares has increased from 18,576,252 to 18,577,078 shares, through the issuance of a total of 826 new shares.

The total current number of outstanding subscription rights amounts to 2,248,427, which entitles their holders (if exercised) to subscribe to 2,723,767 new shares with voting rights in total, namely:

- 302,804 new shares can be issued upon the exercise of one subscription right that was granted in 2016 to Bootstrap Europe S.C.SP. (the "Bootstrap Subscription Right");
- 264,073 new shares can be issued upon the exercise of 91,536 share options that are still outstanding under the 'Executive Share Options' plan for staff members and consultants of the Company, entitling the holder thereof to acquire ca. 2.88 shares when exercising one share option (the "Executive Share Options");
- 1,156,890 new shares can be issued upon the exercise of 1,156,890 share options (each share option having the form of a subscription right) that are still outstanding under the '2018 Share Options' plan for directors, employees and other staff members of the Company and its subsidiaries, entitling the holder thereof to acquire one new share when exercising one share option (the "2018 Share Options"); and
- 1,000,000 new shares can be issued upon the exercise of 1,000,000 share options (each share option having the form of a subscription right) that are still outstanding under the '2021 Share Options' plan for directors, employees and other staff members of the Company and its subsidiaries, entitling the holder thereof to acquire one new share when exercising one share option (the "2021 Share Options").

**For more information, please contact:**

**Sequana Medical**

Lies Vanneste  
Director Investor Relations  
Tel: +32 498 05 35 79  
Email: [IR@sequanamedical.com](mailto:IR@sequanamedical.com)

**LifeSci Advisors**

Guillaume van Renterghem  
Tel: +41 76 735 01 31  
Email: [gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

**About Sequana Medical**

Sequana Medical is a commercial stage medical device company utilizing its proprietary **alfapump**<sup>®</sup> and DSR<sup>®</sup> (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure, with diuretic resistance being widespread. The U.S. market for the **alfapump** resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for DSR and the **alfapump** DSR<sup>®</sup> is estimated to be over €5 billion annually in the U.S. and EU5 by 2026.

The **alfapump** is a unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical's proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.

In the U.S., the Company's key growth market, the **alfapump** has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life. This study is intended to support a future marketing application of the **alfapump** in the U.S. and Canada. In Europe, the **alfapump** is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 **alfapump** systems have been implanted to date.

Sequana Medical has combined its proven **alfapump** and proprietary DSR therapy, and is developing the **alfapump** DSR, a breakthrough approach to fluid overload due to heart failure. RED DESERT, the repeated dose **alfapump** DSR study in diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as

restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of **alfapump** DSR in decompensated heart failure patients is ongoing.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit [www.sequanamedical.com](http://www.sequanamedical.com).

### ***Important Regulatory Disclaimers***

*The **alfapump**<sup>®</sup> system is not currently approved in the United States or Canada. In the United States and Canada, the **alfapump**<sup>®</sup> system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see [www.poseidonstudy.com](http://www.poseidonstudy.com). The DSR<sup>®</sup> therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR<sup>®</sup> therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR<sup>®</sup> therapy and ongoing investigations with the **alfapump**<sup>®</sup> system in Europe, the United States or Canada. DSR<sup>®</sup> and **alfapump** DSR<sup>®</sup> are registered trademarks in Benelux.*

**Note:** ***alfapump**<sup>®</sup> is a registered trademark. DSR<sup>®</sup> and **alfapump** DSR<sup>®</sup> are registered trademarks in the Benelux.*

### ***Forward-looking statements***

*This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.*